{"id":5371,"date":"2026-09-26T05:31:24","date_gmt":"2026-09-26T05:31:24","guid":{"rendered":"https:\/\/www.vaultinsider.top\/?p=5371"},"modified":"2026-09-26T05:31:24","modified_gmt":"2026-09-26T05:31:24","slug":"blue-cross-blue-shield-association-study-patients-quitting-glp-1-drugs-like-wegovy-too-fast-to-achieve-meaningful-weight-loss","status":"publish","type":"post","link":"https:\/\/www.vaultinsider.top\/?p=5371","title":{"rendered":"Blue Cross Blue Shield Association study: Patients quitting GLP-1 drugs like Wegovy too fast to achieve meaningful weight loss"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/fortune.com\/img-assets\/wp-content\/uploads\/2024\/05\/53737234221_6d07b58e60_o-e1716323708759.jpg?w=2048\" \/><\/p>\n<p>As recently as the onset of COVID-19 four years ago, you probably didn\u2019t know what a glucagon-like peptide 1 agonist, or GLP-1 drug, was. But this class of medications, which help people with Type 2 diabetes and obesity lower their blood sugar and promote weight loss, is now a household name.<\/p>\n<div>\n<p class=\"wp-block-paragraph\">\u201cIt\u2019s everywhere,\u201d Dr. Razia Hashmi, Blue Cross Blue Shield Association (BCBSA) vice president of clinical affairs, said Tuesday during a town hall at <em>Fortune<\/em>\u2019s Brainstorm Health conference in Dana Point, Calif. \u201cIt\u2019s part of our conversation. It\u2019s on social media, your family\u2019s talking about it, we\u2019re talking about it in the boardroom, we\u2019re talking about it in the break room. There is, obviously, a lot of excitement about it\u2014the adoption\u2019s been exponential\u2014but there is so much more to learn.\u201d<\/p>\n<p class=\"wp-block-paragraph\">Not all of it is positive, as revealed by a new study conducted by Blue Health Intelligence that examined nearly 170,000 GLP-1 users who were prescribed the medication for weight loss. Released Tuesday, it\u2019s \u201cthe largest-ever study done, real-world evidence study\u201d of the medication, Hashmi said.<\/p>\n<p class=\"wp-block-paragraph\">The study shows patients aren\u2019t taking the medication properly, despite its skyrocketing popularity: Net sales of antiobesity drugs such as semaglutide, or Wegovy, hit $1.1 billion in the second quarter of 2023, per the Congressional Budget Office.<\/p>\n<p class=\"wp-block-paragraph\">Most patients taking GLP-1 drugs for weight management didn\u2019t stay on their prescribed treatment for the minimum 12 weeks, meaning they were unlikely to attain clinically meaningful weight loss. Young adults (aged 18\u201334) were more likely to drop out of treatment sooner, and more than 30% of all patients dropped out after just four weeks, before reaching the targeted dose.<\/p>\n<p class=\"wp-block-paragraph\">The gastrointestinal side effects of GLP-1s, including nausea, vomiting, and diarrhea, may be a reason people don\u2019t complete treatment, the study notes. But because the medication is intended to treat obesity and Type 2 diabetes\u2014both serious, chronic conditions\u2014quitting cold turkey without a doctor\u2019s guidance may be dangerous.<\/p>\n<p class=\"wp-block-paragraph\">\u201cOne has to ask, why?\u201d Hashmi said. One clue, she said, comes from the doctor prescribing the medication: \u201cYour provider matters. If your provider is trained in endocrinology, if they are trained and board-certified in obesity management, the likelihood that you will stay on the treatment is much, much higher.<\/p>\n<p class=\"wp-block-paragraph\">\u201cThe other thing that we found was that each additional visit to your doctor, regardless of specialty, increased your chances of reaching that meaningful weight-loss goal by 60%.\u201d<\/p>\n<p class=\"wp-block-paragraph\">Another finding Hashmi highlighted was that support for diet, nutrition, behavioral health, and side effect management matters. The same goes for health equity; the study revealed people who lived in underserved health regions were less likely to complete 12 weeks of treatment.<\/p>\n<p class=\"wp-block-paragraph\">Andrew Nusca, editorial director of <em>Fortune<\/em>\u2019s Brainstorm conference series, moderated the town hall, which also featured Dr. Rami Bailony, cofounder and CEO of Enara Health. While acknowledging that such research on GLP-1 usage and outcomes is needed, Bailony stressed the drugs should be just one component of obesity management.<\/p>\n<p class=\"wp-block-paragraph\">\u201c[GLP-1s] will change the way we do care, but ultimately, what matters is the framework in which those are delivered,\u201d he said. \u201cOur mission is to deliver personalized, data-driven treatment, and we do that by integrating directly into primary care and cardiology care, and [it] will be the data layer that personalizes that treatment that\u2019s going to make a difference in the end.\u201d<\/p>\n<p class=\"wp-block-paragraph\"><strong>For more on weight management:<\/strong><\/p>\n<\/div>\n<p>#Blue #Cross #Blue #Shield #Association #study #Patients #quitting #GLP1 #drugs #Wegovy #fast #achieve #meaningful #weight #loss<\/p>\n","protected":false},"excerpt":{"rendered":"<p>As recently as the onset of CO&hellip; <\/p>\n","protected":false},"author":1,"featured_media":5372,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[3524,8446,5659,8443,8445,8444,3499,4416,4259,4709,886,3552,2374,8265,4216,3638,8447,1080,8448,4717,1594,3640,3551,3641,3642,8441],"class_list":["post-5371","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance-news","tag-achieve","tag-association","tag-blue","tag-brainstorm-health","tag-cross","tag-diabetes","tag-drugs","tag-editors-picks","tag-fast","tag-glp1","tag-health","tag-loss","tag-meaningful","tag-medicine","tag-obesity","tag-ozempic","tag-patients","tag-pharmaceutical-industry","tag-quitting","tag-shield","tag-study","tag-wegovy","tag-weight","tag-weight-loss","tag-weight-loss-and-diet-control-industry","tag-well-migrated"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Blue Cross Blue Shield Association study: Patients quitting GLP-1 drugs like Wegovy too fast to achieve meaningful weight loss - Finance News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.vaultinsider.top\/?p=5371\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Blue Cross Blue Shield Association study: Patients quitting GLP-1 drugs like Wegovy too fast to achieve meaningful weight loss - Finance News\" \/>\n<meta property=\"og:description\" content=\"As recently as the onset of CO&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.vaultinsider.top\/?p=5371\" \/>\n<meta property=\"og:site_name\" content=\"Finance News\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-26T05:31:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fortune.com\/img-assets\/wp-content\/uploads\/2024\/05\/53737234221_6d07b58e60_o-e1716323708759.jpg?w=2048\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/?p=5371#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/?p=5371\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/#\\\/schema\\\/person\\\/ed40724a3e5d482ce66781a042c3c31e\"},\"headline\":\"Blue Cross Blue Shield Association study: Patients quitting GLP-1 drugs like Wegovy too fast to achieve meaningful weight loss\",\"datePublished\":\"2026-09-26T05:31:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/?p=5371\"},\"wordCount\":603,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/?p=5371#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.vaultinsider.top\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/53737234221_6d07b58e60_o-e1716323708759.jpg\",\"keywords\":[\"achieve\",\"Association\",\"blue\",\"Brainstorm Health\",\"Cross\",\"Diabetes\",\"Drugs\",\"Editor's Picks\",\"fast\",\"GLP1\",\"Health\",\"loss\",\"meaningful\",\"medicine\",\"obesity\",\"Ozempic\",\"Patients\",\"Pharmaceutical Industry\",\"quitting\",\"shield\",\"Study\",\"Wegovy\",\"Weight\",\"Weight Loss\",\"weight-loss and diet control industry\",\"Well Migrated\"],\"articleSection\":[\"Finance News\"],\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.vaultinsider.top\\\/?p=5371#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/?p=5371\",\"url\":\"https:\\\/\\\/www.vaultinsider.top\\\/?p=5371\",\"name\":\"Blue Cross Blue Shield Association study: Patients quitting GLP-1 drugs like Wegovy too fast to achieve meaningful weight loss - Finance News\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/?p=5371#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/?p=5371#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.vaultinsider.top\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/53737234221_6d07b58e60_o-e1716323708759.jpg\",\"datePublished\":\"2026-09-26T05:31:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/#\\\/schema\\\/person\\\/ed40724a3e5d482ce66781a042c3c31e\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/?p=5371#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.vaultinsider.top\\\/?p=5371\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/?p=5371#primaryimage\",\"url\":\"https:\\\/\\\/www.vaultinsider.top\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/53737234221_6d07b58e60_o-e1716323708759.jpg\",\"contentUrl\":\"https:\\\/\\\/www.vaultinsider.top\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/53737234221_6d07b58e60_o-e1716323708759.jpg\",\"width\":1200,\"height\":600},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/?p=5371#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9875\",\"item\":\"https:\\\/\\\/www.vaultinsider.top\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Blue Cross Blue Shield Association study: Patients quitting GLP-1 drugs like Wegovy too fast to achieve meaningful weight loss\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/#website\",\"url\":\"https:\\\/\\\/www.vaultinsider.top\\\/\",\"name\":\"Finance News\",\"description\":\"Just another Finance News site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.vaultinsider.top\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/#\\\/schema\\\/person\\\/ed40724a3e5d482ce66781a042c3c31e\",\"name\":\"admin\",\"url\":\"https:\\\/\\\/www.vaultinsider.top\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Blue Cross Blue Shield Association study: Patients quitting GLP-1 drugs like Wegovy too fast to achieve meaningful weight loss - Finance News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.vaultinsider.top\/?p=5371","og_locale":"zh_CN","og_type":"article","og_title":"Blue Cross Blue Shield Association study: Patients quitting GLP-1 drugs like Wegovy too fast to achieve meaningful weight loss - Finance News","og_description":"As recently as the onset of CO&hellip;","og_url":"https:\/\/www.vaultinsider.top\/?p=5371","og_site_name":"Finance News","article_published_time":"2026-09-26T05:31:24+00:00","og_image":[{"url":"https:\/\/fortune.com\/img-assets\/wp-content\/uploads\/2024\/05\/53737234221_6d07b58e60_o-e1716323708759.jpg?w=2048","type":"","width":"","height":""}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005":"admin","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"3 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.vaultinsider.top\/?p=5371#article","isPartOf":{"@id":"https:\/\/www.vaultinsider.top\/?p=5371"},"author":{"name":"admin","@id":"https:\/\/www.vaultinsider.top\/#\/schema\/person\/ed40724a3e5d482ce66781a042c3c31e"},"headline":"Blue Cross Blue Shield Association study: Patients quitting GLP-1 drugs like Wegovy too fast to achieve meaningful weight loss","datePublished":"2026-09-26T05:31:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.vaultinsider.top\/?p=5371"},"wordCount":603,"commentCount":0,"image":{"@id":"https:\/\/www.vaultinsider.top\/?p=5371#primaryimage"},"thumbnailUrl":"https:\/\/www.vaultinsider.top\/wp-content\/uploads\/2026\/09\/53737234221_6d07b58e60_o-e1716323708759.jpg","keywords":["achieve","Association","blue","Brainstorm Health","Cross","Diabetes","Drugs","Editor's Picks","fast","GLP1","Health","loss","meaningful","medicine","obesity","Ozempic","Patients","Pharmaceutical Industry","quitting","shield","Study","Wegovy","Weight","Weight Loss","weight-loss and diet control industry","Well Migrated"],"articleSection":["Finance News"],"inLanguage":"zh-Hans","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.vaultinsider.top\/?p=5371#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.vaultinsider.top\/?p=5371","url":"https:\/\/www.vaultinsider.top\/?p=5371","name":"Blue Cross Blue Shield Association study: Patients quitting GLP-1 drugs like Wegovy too fast to achieve meaningful weight loss - Finance News","isPartOf":{"@id":"https:\/\/www.vaultinsider.top\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.vaultinsider.top\/?p=5371#primaryimage"},"image":{"@id":"https:\/\/www.vaultinsider.top\/?p=5371#primaryimage"},"thumbnailUrl":"https:\/\/www.vaultinsider.top\/wp-content\/uploads\/2026\/09\/53737234221_6d07b58e60_o-e1716323708759.jpg","datePublished":"2026-09-26T05:31:24+00:00","author":{"@id":"https:\/\/www.vaultinsider.top\/#\/schema\/person\/ed40724a3e5d482ce66781a042c3c31e"},"breadcrumb":{"@id":"https:\/\/www.vaultinsider.top\/?p=5371#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.vaultinsider.top\/?p=5371"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/www.vaultinsider.top\/?p=5371#primaryimage","url":"https:\/\/www.vaultinsider.top\/wp-content\/uploads\/2026\/09\/53737234221_6d07b58e60_o-e1716323708759.jpg","contentUrl":"https:\/\/www.vaultinsider.top\/wp-content\/uploads\/2026\/09\/53737234221_6d07b58e60_o-e1716323708759.jpg","width":1200,"height":600},{"@type":"BreadcrumbList","@id":"https:\/\/www.vaultinsider.top\/?p=5371#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9875","item":"https:\/\/www.vaultinsider.top\/"},{"@type":"ListItem","position":2,"name":"Blue Cross Blue Shield Association study: Patients quitting GLP-1 drugs like Wegovy too fast to achieve meaningful weight loss"}]},{"@type":"WebSite","@id":"https:\/\/www.vaultinsider.top\/#website","url":"https:\/\/www.vaultinsider.top\/","name":"Finance News","description":"Just another Finance News site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.vaultinsider.top\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Person","@id":"https:\/\/www.vaultinsider.top\/#\/schema\/person\/ed40724a3e5d482ce66781a042c3c31e","name":"admin","url":"https:\/\/www.vaultinsider.top\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/www.vaultinsider.top\/index.php?rest_route=\/wp\/v2\/posts\/5371","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.vaultinsider.top\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.vaultinsider.top\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.vaultinsider.top\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.vaultinsider.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5371"}],"version-history":[{"count":0,"href":"https:\/\/www.vaultinsider.top\/index.php?rest_route=\/wp\/v2\/posts\/5371\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.vaultinsider.top\/index.php?rest_route=\/wp\/v2\/media\/5372"}],"wp:attachment":[{"href":"https:\/\/www.vaultinsider.top\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5371"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.vaultinsider.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5371"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.vaultinsider.top\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5371"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}